EMD 525797
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colorectal and Ovarian Cancer Patients With Liver Metastases
Conditions
Colorectal and Ovarian Cancer Patients With Liver Metastases
Trial Timeline
Feb 1, 2009 → Nov 1, 2013
NCT ID
NCT00848510About EMD 525797
EMD 525797 is a phase 1 stage product being developed by Merck for Colorectal and Ovarian Cancer Patients With Liver Metastases. The current trial status is completed. This product is registered under clinical trial identifier NCT00848510. Target conditions include Colorectal and Ovarian Cancer Patients With Liver Metastases.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00848510 | Phase 1 | Completed |
| NCT00958477 | Phase 1 | Completed |
Competing Products
20 competing products in Colorectal and Ovarian Cancer Patients With Liver Metastases